Aikin Huɗu na Ucleic acid amplifications don gano SARS-2-2 a Habasha

Na gode da ziyartar yanayi.com. Kuna amfani da sigar mai bincike tare da iyakance tallafin CSS. Don mafi kyawun gogewa, muna ba da shawarar cewa kayi amfani da sabuntawa (ko kashe yanayin dacewa a cikin Internet Explorer). Bugu da kari, don tabbatar da ci gaba mai gudana, muna nuna shafin ba tare da salon da javascript ba.
Nuna wani carousel na nunin faifai guda ɗaya. Yi amfani da Buttons na baya don motsawa ta nunin faifai guda uku a lokaci guda, ko amfani da maɓallin kewayon a ƙarshen don motsawa ta hanyar hawa uku a lokaci guda.
Tun daga shekarar 2019 Coronavirus cuta (COVID-19) Barkewar cuta, da yawa suna haɓaka gwaje-gwaje da yawa a duniya kuma sun zama daidaitattun abubuwa. Kodayake gwaje-gwaje da yawa sun ci gaba da sauri kuma ana amfani da su don gwaje-gwaje na ƙwaƙwalwar ƙwaƙwalwa, ba a kimanta aikin waɗannan gwaje-gwaje ba a cikin saiti iri-iri. Sabili da haka, wannan binciken yayi na kimanta aikin na Abb-2, DANENE Gene, BGI, da shafa maƙasudin dabaru (CRS). An gudanar da binciken ne a Cibiyar Lafiya ta Jama'a ta Habasha ce daga 1 zuwa 30 Disamba 2020. An fitar da samfurori na Nasopharyna ta amfani da tsarin Quanamp RNA. Daga cikin samfurori 164, 59.1% sun kasance tabbatacce kuma 40.9% sun kasance mara kyau ga CRS. Sansure Biotech Overitvarevity ya kasance mai mahimmanci kaɗan idan aka kwatanta da CRS (P <.05). Sansure Biotech Overitvarevity ya kasance mai mahimmanci kaɗan idan aka kwatanta da CRS (P <.05). Fоложительныеельныеельныеельные резьныдельныдельныдельe Sansure game da kyakkyawan sakamako na kwantar da hankali ya kasance da ƙananan idan aka kwatanta da CRS (P <.05).与 crs 相比, Sansure Biotech 的 阳性率显着较低 (P <0.05).与 crs 相比, Sansure Biotech 的 阳性率显着较低 (P <0.05). У ыо значительно меньшаторатов резулортов пенулортов пенулортов пенулортов пенулоратов резуловтению Sansure Biotech yana da ƙarancin ingantaccen sakamako idan aka kwatanta da CRS (P <.05).Yarjejeniyar gaba daya na binciken hudu na 96.3-100% idan aka kwatanta da CRS. Baya ga ƙarancin adadin ɓoyayyiyar ɓoyayyiyar halittar ilimin halittar ilimin halittar ilimin halittu lafiya, wasan kwaikwayon na Assim ɗin ya kusan kama da haka. Saboda haka, da Sansuri na Spotech [Binciken bincike kawai (Ruo)] Assayi yana buƙatar ƙarin inganci don amfaninta a Habasha. A ƙarshe, ya kamata a yi la'akari da ƙarin bincike don kimanta kafar kafada tare da da'awar masana'anta da ta ƙira.
Gwajin dakin gwaje-gwaje wani bangare ne na Hukumar Lafiya ta Duniya (Wanene) Tsarin dabarun Coronavirus Cutar Coronavirus Cutar Coronavirus 2019 (CVID-19) shirya da kuma amsa (spp). Waɗanda ke ba da shawara ga cewa ƙasashe suna buƙatar gina ƙarfin dakin gwaje-gwaje don inganta shirye-shiryen, gudanar da lamari yadda ya dace, rawa da sauri martani ga ƙayyadaddun lafiyar jama'a. Wannan yana nuna cewa rawar dakin gwaje-gwaje shine mabuɗin don nuna cutar da cutar ta hanyar fitowar masu kamancewar yanayi da sarrafa yaduwar su.
Cigaban COVID-19 yana buƙatar ɓoyayyiyar bayanai da bayanan likita, alamu na sirri / alamu, da na'urar ɗakin gwaje-gwaje2. Tunda aka ruwaito fashewar covid-19 a Wuhan, a China, da yawa na samar da receification gwaje-gwaje (naats) a duniya. An yi amfani da pollymripi na ainihi na ainihi na gaske. Ganowar kwayoyin halittar SARS-2-2 yawanci suna dogara ne da Gene ne na N (E (FLELP PRELP (RNALP DRARSH (RNACK (RNADRP (RNADRP (RNADRP (RNADRP (RNADRP (RNALP. Gene) yankin da aka gano daga hoto ko bidiyo mai zagaya. An dauke su a matsayin manyan yankuna da aka kiyaye shi a cikin kwayoyin ko bidiyo mai zagi don fitarwa ta ƙwayar cuta4. Daga cikin wadannan halittar, rdrp da Eneres suna da babban bincike na ganowa, yayin da Nen nen yana da karancin bincike na bincike na yau da kullun5.
Aikin PCR na PCR na iya bambanta dangane da abubuwa daban-daban kamar: hakar kayan aiki / amplication / hanyar hakar, ingancin fitarwa, ingancin injin da sauran kayan aiki. Kamar yadda Afrilu 2080, sama da guda 48 na'urorin bincike daban daban daban daban daban daban daban daban daban-daban daga kasashe tara sun sami izinin gaggawa (EUA) don cututtukan COVID-196. A cikin Habasha, sama da 14 na yau da kullun PCR na yau da kullun ana amfani da shi don ganowa na PCR na SARS-2 a 26 cibiyoyin kiwon lafiya na gwamnati, gami da Abi 7500, Roche 48000 da ƙira-Studio7. Bugu da kari, da yawa gwajin komputa na PCR suna samuwa, kamar gwajin Gene na Dana. Kodayake RTT-PCR mai mahimmanci ne, wasu marasa lafiya da CoviD-19 ba da rahoton sakamako na ƙwayoyin cuta ba saboda tarin marasa nauyi, jigilar kaya, ajiya da kulawa, da gwaji na gwaji. yanayi da ayyukan ma'aikata8. Bugu da kari, samfurin ko sarrafa turnandling, maimaitawa kofa, da kuma m / rna-reshes SARS na kwantar da hankali a cikin RRT-PCR9 'yan wasa. Don haka, ya bayyana sarai cewa gwaje-gwajen PCR za su iya gano ƙwararrun ƙwayoyin halittun, kamar yadda ba za su iya bambance tsakanin da gaske aiki da kayan kwalliya ba da soalcy, don haka gwaje-gwajen na iya gano dillalai ne kawai. Saboda haka, yana da mahimmanci a tantance aikin bincike ta amfani da daidaitattun hanyoyin a cikin saitin. Kodayake ana samun reagents da yawa a Cibiyar Lafiya ta Jama'a ta Habasha da kuma a duk faɗin ƙasar ba tukuna an ruwaito ingancinsu. Saboda haka, wannan binciken yayi na kimanta aikin kwatancen kasuwanci don gano kayan SARS-2-2 ta RRT-PCR ta amfani da samfuran asibiti.
Jimlar mahalarta 164 da ake zargi da COVID-19 an saka su cikin wannan binciken. Mafi yawan samfurori sun fito ne daga cibiyoyin jiyya (118/164 = 72%), yayin da ragowar mahalarta 46 (28%) daga cibiyoyin jiyya. Daga cikin mahalarta ba a bi da shi a tsakiyar ba, 15 (9.1%) sun sami laifin da ake zargi da laifin da aka yi. Casa'in da uku (56.7%) mahalarta) maza ne, da ma'ana (± SD) Shekarun mahalarta ya kasance 31.10 (± 11.82) shekaru.
A cikin wannan binciken, tabbatacce kuma mara kyau gwargwado na gwaje-gwaje guda huɗu don COVID-19 sun ƙaddara. Don haka, ingantattun kudaden da ke cikin Abbott SARS-Cov-2 Assayi, Dayan Assayi 2019-NCOV Assay ne 59.1%, 58.5%, 57.9% da 55.5% bi da bi. Kyakkyawan ƙa'idodi mai kyau da mummunan abu (CRS) sun kasance 97 (59.1%) da 67 (40.9%), bi da bi (tebur 1). A cikin wannan binciken, fassarar 'yan CRS sun danganta ne da "kowane kyakkyawan" tabbataccen "mai kyau, inda sakamakon gwajin guda huɗu, da yawa sakamakon gwajin da aka ba shi sakamako mai kyau ko mara kyau.
A cikin wannan binciken, mun sami wata yarjejeniya mara kyau (NPA) na 100% (95% ci 94.6-100) ga dukkan nazarin idan aka kwatanta da CRS. Binciken na Spotechnology na sirri nazarin ya nuna karamin pa na 93.8% (95% ci 87.2-97.1) da kuma Dayan NCOV (95% ci 96.6-99.9). A cikin bambanci, Yarjejeniyar gaba ɗaya tsakanin SARS-2-2 Bgi assay da kuma Sansuri na Sansiti 2019-NCOV Assay ne 98.8% da 96.3%, bi da bi (Tebur 2).
Sakamakon Cohen ta KAPPA na yarjejeniya tsakanin CRS da Absott SSS-Cov-2 sakamakon assay ya kasance cikakken daidaitacce (k = 1.00). Hakazalika, koyarwar Cohen ta KAPPA ta gano ta hanyar DANALE na shekarar 2019-NCOV, SARS. " A cikin wannan bincike na comative, gwajin ChI-Square (gwajin McNEM) ya nuna cewa yana da matukar muhimmanci daga sakamakon CRS (P = 0.031).
Kamar yadda aka nuna a cikin siffa.1 Kashi na mafi ƙasƙanci CT (<20 CT) na Abbott SARS-Cov-2 Assayi (<20 CT) ya kasance 50. 35% da babban darajar CT (36-3% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2%. 1 Kashi na mafi ƙasƙanci CT (<20 CT) na Abbott SARS-Cov-2 Assayi (<20 CT) ya kasance 50. 35% da babban darajar CT (36-3% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2% CT) ya kasance 3.2%.Kamar yadda aka nuna a cikin siffa.1, Процент н (<20 ct) значения CT (<20 ct) анач-ct 87,5 Omar Енали Aff1a / B анализачтогия Ct CT) Составляло 3,2%. 1, yawan mafi ƙarancin darajar CT (<< 20 CT) ya nazarin ƙimar CT (36-3%, kuma darajar CT (36-40 CT) ya lissafta na 3.2%.如图, Abbott SARS-COV-2 检测 (结合 rar 和 n 基因 (<20 ct ct 值显示低 50 50%, ct ct)的 百分比为 3.2%. Kamar yadda aka nuna a hoto 1, mafi ƙasƙanci CT darajar kashi (<20 CT) na gwajin Sansure Bicelonan (300), 高 CT 值 (36-4-0 ct) 的 32.3 3.2%. Mак показано назнке 1, аначение Прочение Ct (<очение Ct (<< 20 ct) в размере 8,6%, значение Ct значение Ct всследовализкий CT. Kamar yadda aka nuna a cikin Hoto na 1, Abbott Sur-cov-2 Assayi (<20 CT Gene) yana da mafi ƙarancin ƙwayar cuta ta 2019. Процент значений (<20 ct) проктор ct (36-40 CT) составл 3,2%. Kashi na yawan dabi'u (<20 CT) ya kasance 50.3%, da kuma yawan babban darajar CT (36-40 CT) ya kasance 3.2%.Abbott SARS-2-2 B gwajin CT dabi'u sama da 30. A gefe guda, a kan Bgi SARS-2-2 Assay orf1a / B ya sami babban darajar CT (> 36 CT kashi ɗaya ya kasance 4% (Fig. 1). A gefe guda, a kan Bgi SARS-2-2 Assay orf1a / B ya sami babban darajar CT (> 36 CT kashi ɗaya ya kasance 4% (Fig. 1). Думороны, в Ачен Orf CT (> 36 ct В тентие составлялал 4% (рис. 1). A gefe guda, a cikin bincike na Bgi SARS-Cov-2 Gene gene orf1a / b yana da babban darajar CT (> 36 CT), kashi na wanda ya kasance 4% (Fig. 1).另 一, 在 BGI SARS-COV-2 检测 中, ORF1A / B 基因具基因具 高 CT) 的 百分比为 4. 36 On the other hand, in BGI SARS-CoV-2 detection, the percentage of ORF1a/b gene with high Ct value (>36 Ct) is 4% (Figure 1). Дутой стороны, в Аголизе Bgi SSS-Cov-2 провтавл 4% (рис. 1). A gefe guda, a cikin bincike na Bgi-2, kashi na Orf1a / B Gene tare da dabi'u masu daraja (> 36 CT) ya kasance 4% (Fig. 1).
A cikin wannan binciken, mun ɗauki samfurori 164 na NasopharyNeal. Ga kowane nau'in magunguna, RNA Natheration da amplification an yi ta amfani da hanyoyin da kuma abubuwan da aka ba da shawarar da masana'antun da suka bayar.
Wannan binciken ya nuna cewa jarabawar Abbott don SARS, 2 tana da aikin gano iri ɗaya kamar CRS, tare da tabbataccen concordance. Yarjejeniyar Kappa ta 1.00, wacce ke nuna cikakkiyar yarjejeniya da CRS. Nazarin da ake iya kama da Jami'ar Washington a cikin Amurka ta gano cewa tunanin mutum gaba ɗaya da kuma ingancin gwajin Abbot don SARS-Assime (LDA) na CDC. 11. Tsarin Ganowar COV-2 na COV-2 ya dogara ne akan gano abubuwa na lokaci guda na N da RordRP. Nazari a Vienna, Austria kuma ya nuna cewa babban kayan samar da kayan girke-girke da gano adadin masu tasowa da yawaita da yawaita da kuma inganta ingancin ganowa13. Don haka, cikakkiyar wasan ne na Abbot na COV-2-2 na yau da kullun ana iya danganta shi da tsarin ganowa na dandamali wanda lokaci guda ya gano babban samfuran kwastomomi (0.5 ml), kuma yana amfani da babban adadin masara (40 μl).
Sakamakon bincikenmu ya kuma nuna cewa gano gwajin Dayan Genetic kusan iri ɗaya ne na CRS. Wannan ya yi daidai da nazarin14 da aka gudanar a Jami'ar Anhui a Jami'ar Anhui a Huainan, China, da kuma da'awar masana'anta na 100% yarjejeniya. Duk da rahotanni masu daidaitawa, samfurin daya ya karya ne mara kyau bayan ya sake yin gyara iri daya, amma ya kasance mai kyau a cikin Abbot din Abb-2-2 da Sanssion Kansuwa. Wannan yana nuna cewa akwai canji a sakamakon nau'ikan abubuwan da suka faru. Duk da haka, a cikin binciken da aka aiwatar a China1, sakamakon na Dano Gene Assay ya kasance daban-daban (P <0.05) idan aka kwatanta da Asabar dinsu na labalinsu. Duk da haka, a cikin binciken da aka aiwatar a China1, sakamakon na Dano Gene Assay ya kasance daban-daban (P <0.05) idan aka kwatanta da Asabar dinsu na labalinsu. Еменее, в Сследовато в олие15, резтате1отае15, резтате1отате15отачино осеачичато отлинота Banати лабораторыорногоггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггггногонно анализа. Koyaya, a cikin binciken a cikin binciken a China15 sakamakon binciken Gene ne ya bambanta sosai (shafi <0.05) daga binciken tunani na dakin gwaje-gwaje.然而, 在在 的 研究 中 15, 大安基因检测 的 的 的显着差异 (P <.05).然而 国进行国进行 的 研究 中 15 中 的 的 的显着差 <0.05 Одако всследованнае15, резтачичались (P <0,05) по по с авнению с Егениюталонным лабораторным Естом. Koyaya, a cikin binciken a China15, sakamakon gwajin asalin Daisic ya bambanta sosai (shafi <0.05) idan aka kwatanta da gwajin dakin gwaje-gwaje.Wannan hiljin na iya zama saboda tsananin tunanin gwajin gwaji don gano SARS-2, da kuma ƙarin bincike na iya zama mahimmanci don sanin dalilin.
Bugu da kari, bincikenmu ya kimanta kwatancen kwalliyar da SARS-2 Bgi assay tare da CRS, PPA = 9%), yarjejeniya ta korau (opa). ). = 98.8%). Halittar da Cohen ta KAPPA sun nuna kyakkyawar yarjejeniya (K = 0.975). Nazarin a cikin Netherlands16 da China15 sun nuna sakamako mai mahimmanci. Gwajin BARS-2-2-2 shine Gene guda ɗaya (OrF1A / B) Gwajin Gano ta amfani da 10 μl Amplification / Gano eluate. Duk da yarjejeniya mai kyau mai kyau tare da sakamakon mu na nasiha, masu binciken da aka rasa samfurori biyu masu kyau (1.22%) na jimlar samfurin. Wannan na iya samun manyan abubuwan asibiti don watsa mai saurin lalacewa a duka mara lafiya da matakan al'umma.
Wani bincike na kwatantawa da aka haɗa a cikin wannan binciken shi ne Sansuri na Sansarshen Biotech NCOV 2019 RRT-PCR (RO) Assay; Overarin wasan daidai shine kashi 96.3%. Hakanan karfin yarjejeniyar an ƙaddara shi da darajar Kafar ta Cohen, wanda shine 0.925, yana nuna cikakken yarjejeniya da CRS. Haka kuma, sakamakonmu iri ɗaya ne ga nazarin da aka gudanar a Jami'ar Tsohon Jami'ar Tsakiyar Jami'ar Liuzhou, kuma a Ma'aikatar dakin asibiti na Liuzhou, Liuzhou City, Barcelona7. Duk da cewa an yi rikodin na yau da kullun Concorordance, gwajin Chi-Square (gwajin MacNOM) ya nuna cewa bambance-bambancen da ke da Sansotech mai mahimmanci idan aka yi da CRS (P <0.005). Duk da cewa an yi rikodin na yau da kullun Concorordance, gwajin Chi-Square (gwajin MacNOM) ya nuna cewa bambance-bambancen da ke da Sansotech mai mahimmanci idan aka yi da CRS (P <0.005). Несмотря на то, что было зафиксировано указанное выше хорошее статистическое соответствие, критерий хи-квадрат (критер мапемарапато рдо рдето резульеато рето Срето зето зеАчи савет Среатоначет Среато равет статиюасратиюазвичатисравначисраввнатиюазличатисравначисравначисравначисравнато аеазинатисравет статисравначтиюазви савначтиюазбинато аето Среато 0,005). Kodayake an yi yarjejeniya mai kyau na zamani da ke sama, gwajin Chi-Square (gwajin McNERE) ya nuna cewa bambance-bambancen da ke da Sansothe da Assayi da CRS (P <0.005).的 统计 致性致性, 但卡方检验 (Macnemar 检验) 表明, Sansure Biotech 检测 的 结果与 crs 相比具 统计学显着差异 (P <0.005).统计 统计 上述致性, 但 致性 致性, 但 检验 ((macnemar 检验 ,, macnemar 检验,, Sans 检测 具具 crs 相比 具 显着 ((P <0 0)))) Несмотря на отмеченное выше хорошее статистическое соответствие, критерий хи-квадрат (критерий Макнемара) показал Атистиюески зазницу (P <s 5,005) МЕжіду Анализомунализомунализомунализомунализомунализомунализомунализомунализомунализомунализомунализом Duk da kyakkyawar yarjejeniyar ilimin ta da ke sama, gwajin Chi-Square (gwajin McNelar) ya nuna bambanci mai mahimmanci (P <0 00055) Tsakanin Sansuri na kashin baya.An gano samfurori shida (3.66%) an gano su zama mara misalin karya idan aka kwatanta da CRS (Teburin Gumi 1); Wannan yana da matukar muhimmanci, musamman ma ya ba da matsalolin watsawa na kwayar cutar. Hakanan bayanan da ke sama suna tallafawa wannan karancin ganowa15.
A cikin wannan binciken, ƙa'idar CT an ƙaddara ga kowane assasday da dandamali na nufin darajar CT a cikin ABBUT SARK-COV-2 Assayi. Wannan sakamakon na iya danganta da tsarin gwajin kwayoyin halittar halittar halittar sashi don ganowar SARS-2-2. Sabili da haka, bisa ga Hoto 1, 87.6% na sakamakon COV-2 yana da ƙimar CT a ƙasa 20. Kawai karamin adadin sakamakon samfurin (12.4%) sun kasance a cikin kewayon 20-30. CT dabi'u sama da 30 ba a yi rikodin ba. Baya ga amfani da tsarin gwajin SARS-COV-2, wannan sakamakon na iya danganta da iyakar ƙananan gano (32.5 RNA. ML) 19.
Wannan binciken yana da wasu iyakoki: Da fari dai, ba mu da hanyoyin daidaitawa / tunani [kamar kayan gwaje-gwaje ko kuma wasu gwajin dakin gwaje-gwaje (LDA)] saboda rashin albarkatu. Na biyu, duk samfurori da aka yi amfani da su a wannan binciken akwai Nasopharynes Swabs, da na uku, girman samfurinmu ya karami.
Wannan binciken ya kwatanta wasan kwaikwayon na RRT-PCR hardbs na SARS-HOV-2 ta amfani da samfuran NasopharyNeal. Dukkanin abubuwan da suka faru sun kusan aiwatar da aiki, in banda sansuri na kansure assay. Bayan haka, an gano ƙarancin adadin ɓarna a cikin SansRE na Biotech assay idan aka kwatanta da CRS (P <0.05). Bayan haka, an gano ƙarancin adadin ɓarna a cikin SansRE na Biotech assay idan aka kwatanta da CRS (P <0.05). Оме тоггг, в тесте Sanssi Bugu da kari, gwajin Sansure Biotech ya nuna karancin kashi na kyakkyawan sakamako idan aka kwatanta da CRS (shafi <0.05).此外, 与 CRS 相比, Sansure Biotech 检测 的 阳性率较低 (shafi <.05).此外, 与 CRS 相比, Sansure Biotech 检测 的 阳性率较低 (shafi <.05). Оме тиз Sansure kannada Tansure Kawasaki 1о Сре K. Bugu da kari, da Sansure Biotech Asay yana da karancin kudi idan aka kwatanta da CRS (P <0.05).Sansuri Biotech NCOV 2019 (RUO) nazarin na PPA, NPA da Yarjejeniyar Masara da 93.5% tare da karfin yarjejeniyar yarjejeniya ta 0.925. A ƙarshe, Sansure Biotech assay (Ruo) yana buƙatar ƙarin inganci don amfani a Habasha, kuma ya kamata a ɗauki ƙarin bincike don kimanta da'awar mutum.
Asibitin karatu na karatu a wuraren kiwon lafiya huɗu a Addi Ababa, Cibiyar Cocin Millennaium, da St. Bitrus na kwararru na kwararru. An tattara bayanan a tsakanin Disamba 1 da 31, 2020. An zaɓi kayan aikin likita don wannan binciken da aka zaɓa bisa yawan lokuta na ƙwayoyin cuta da kuma manyan cibiyoyin kulawa da ke cikin birni. Hakanan, kayan kida, gami da Abi 7500 da Abbott na masu samar da kayan aikin na PCT, kuma an zaɓi abubuwan da aka gano PCR guda hudu a cikin Habasha sun yi amfani da aƙalla huɗu. Gwajin Gem, gwajin Abbott SARS-2, gwajin yana da musayar gwajin kwayoyin halitta, da gwajin SARS-2 da aka yi yayin binciken).
Gwaji don SARS-2-2 an yi shi ne daga 1 zuwa 30 Disamba 2020 Ta amfani da 3 ml na Motar hoto ko bidiyo mai zagaya yanar gizo) daga cikin bincike game da EPHI. An tattara samfurori na Nasopharyneal ta hanyar horar da sasple na masu sasple kuma an aika zuwa EPHI a cikin fakitoci sau uku. Kafin aikin kadada acid, an sanya kowane samfurin lambar tantancewa ta musamman. Ana yin hakar halitta daga kowane samfurin nan da nan yayin isowa ta amfani da jagora da hanyoyin hakar ta atomatik. Don haka, don hakar ta atomatik na Abbott M2000, har da 0.8 ml (wanda ya wuce ml ml (a abbott mlickular Inc. Des, Amurka). ) Batch na 96 [92 samfurori, samfuran sarrafawa guda biyu da aka haɗa (NTC)] an haɗa da shi a cikin tsari gaba ɗaya na SARS-2-2 (EUA) a cikin ainihin lokaci. ma'adinai. Hakazalika, don hakar hannu, yi amfani da samfurori iri ɗaya (don hakar ta atomatik da gano). Saboda haka, a duk faɗin samfuran, a cikin samfuran μl 140 an haɗa su da amfani da samfuran guda 20 (ciki har zuwa samfuran 20, sarrafawa biyu) a cikin zagaye tara. Da hannu an fitar da Elules da aka samo kuma an gano shi ta amfani da mailler mai linzami na Abi 7500 ta amfani da SARS-2 Bgi Assay, da kuma sansure asaych assay.
Kadaici na atomatik da tsarkakewar SARS-2 Virts Virts ta amfani da ka'idodin Magnet DNA Samfuran shirye-shiryen Samfuran Samfuran Magana. Ba a aiwatar da samfurori da kuma Solubilation na ƙwayoyin cuta masu zagaya yanar gizo da sauri ana yin amfani da abin wanka da Guanidinate ba don tsoratar da rnase. Daga nan sai aka raba shi daga furotin ta rabuwa da lokaci ta amfani da silica, watau alkalined ph na silica (Sio2). Mataki na Rinesing yana cire ragowar sunadarai da tarkace don samar da ingantaccen bayani. Bayyanannun RNA aka ware daga microcarticles-tushen microcartication ta amfani da kayan aikin magnetic na kayan aiki naúrar 2020,21. A gefe guda, warewar hannu da tsarkakewa na RNA ne da za'ayi ta hanyar shafin prop shafi a tsaye ta amfani da centrifugation maimakon sihiri da rabuwa da micropartications daga m micropartications daga m micropartications da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abropartications daga m Microcartications da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abroparticles da rarrabuwa abropartications daga m Microcartications daga Mikguo.
The Abbott Real-Time SARS-CoV-2 Detection Test (Abbott Molecular, Inc.) was performed according to the manufacturer's instructions, which received EUA19,22 from the WHO and FDA. A cikin wannan yarjejeniya, samfurin kayan aikin kafin hakar ana yin shi a cikin wanka na ruwa a 56 ° C na 30 min. Bayan da ba shi da kwayar cutar, hakar nucleic acid a kan kayan aikin PROT M2000 daga 0.5 ml vtm ta amfani da wani tsarin tsarin. Dangane da masana'anta. An yi fitarwa da ganowa ta amfani da kayan aikin ABBott RT-PCR PCR, kuma an yi gano abubuwa na Dual don Rdrp kuma na kwayoyin halitta. Rox) da VIC P (picrietary fenti) don niyya da gano abubuwan sarrafawa na cikin gida 19.
Hanyar gano ingancin wannan kit ɗin yana dogara ne akan fasahar mataki ɗaya na PCR. An zabi na kwayoyin halittar orf1a / b kuma an zabi shi kamar yadda Fasaha ta Danan ta gano faduwar yankin da aka bayar. Takamaiman farashi da masu bincike (N Genevespcoment Probes da aka yiwa alama tare da Fig, orf1a / B probes da vic) an tsara shi don gano SARS-2 rnon a cikin samfurori. An shirya na ƙarshe da aka shirya da Masters da Master na ƙara 5 μL na Elelun zuwa 20 μL Mix zuwa girma na ƙarshe na 25 μL. An yi amfani da amplification da gano lokaci guda akan Abi 750024 na ainihin kayan aikin PCR na ainihi.
An gano halittar orf1a / b kuma an gano shi ta amfani da kayan kwalliya na sirri na NCOV NCOv Att acid (Mai kyalli PCR na ganowa). Shirya takamaiman binciken ga kowane mai manufa ta hanyar zabar fam da Fati na Orf1a / B da tashar Rox don Narar Gene. Ga wannan kit ɗin Assay, eluif da Master Mijents an ƙara kamar haka: Shirya 12 μl Master Miagent da 20 μL Elted samfurin don gano / amplification samfurin don gano / amplification. An yi amfani da Real-lokaci PCR Abi 750025 don Amplification / Gano.
Gwajin BARS-2-2 Yankin manufa yana cikin yankin Orf1a / B na Ganyen SARS-2, wanda shine hanyar gano Gene guda ɗaya. Bugu da kari, kwarewar gidan mutum β-Actin wani gene mai manufa ne wanda aka tsara. An shirya Mubangiji da aka haɗa ta hanyar haɗawa 20 μL na Jagora Haɗa gaba da 10 μL na fitar da abubuwan da aka fitar da RNA samfurin a cikin sananniyar farantin26. Anyi amfani da kayan aikin Abi 7500 na kayan aiki na ainihi na kayan aikin PCR na kayan aiki don amplification da ganowa. Dukkanin ampleic acid amplification, PCR gudanar da yanayin kowane Assurn, kuma fassarar sakamakon an yi shi gwargwadon ƙirar masana'anta (Table 3).
A cikin wannan bincike na compatiative, ba mu yi amfani da hanyar daidaitaccen tsarin tunani ba don sanin cikakken yarjejeniya (tabbatacce, mara kyau) da sauran sigogin kwatancen don nazarin guda huɗu. Kowace kwatancen gwaji na gwaji tare da CRS, a cikin wannan binciken an saita shi ta hanyar Mulkin "Duk wani tabbaci" kuma an ƙaddara shi, ba mu yi amfani da sakamako guda ɗaya ba, ba mu yi amfani da sakamakon gwajin gwaji biyu ba. Bugu da kari, dangane da isar da COVID-19, sakamakon mummunan sakamako yana da haɗari fiye da kyakkyawan sakamako na karya. Sabili da haka, a ce "tabbatacce" da kyau kamar yadda yakamata a sakamakon CRS ɗin, aƙalla gwaje-gwaje biyu masu kyau dole ne su kasance masu inganci, ma'ana aƙalla sakamako mai kyau ne. Don haka, daga sakamakon gwaji hudu, sakamakon gwajin biyu ko sama da haka suna ba da sakamako guda mai gaskiya ko mara kyau18,27.
An tattara bayanai ta amfani da siffofin hakar bayanai na tsari, shigarwar bayanai da bincike ana amfani da amfani da software na ƙididdigar ƙididdiga da sigar SPS 23.0 don bayanin kwatancen. Tabbatacce, mara kyau, an bincika Yarjejeniyar Kasar Koda, kuma ana amfani da maki na Kaffa don tantance darajar yarjejeniyar kowace hanyar CRS. Kappa values ​​​​are interpreted as follows: 0.01 to 0.20 for mild agreement, 0.21 to 0.40 for general agreement, 0.41-0.60 for moderate agreement, 0.61-0.80 for major agreement and 0.81-0.99 for complete agreement28.
An samo tsabtace ɗabi'a daga Jami'ar Addis Ababa da duk ayyukan gwaji na binciken kwayar cutar Habasha. Lambar tunani don lasisi na EPHI na EPHI shine EPHI / IPB-279-2020. Dukkanin hanyoyin da aka yi amfani da duk hanyoyin da shawarwarin da kuma tanada manyan jagororin kasar Habasha don lura da COVID-19. Bugu da kari, an samu izinin sanarwar sanarwa daga dukkan mahalarta nazarin kafin su kasance cikin binciken.
Duk bayanan da aka samu ko aka bincika a cikin wannan binciken an haɗa su cikin wannan labarin da aka buga. Bayanai da ke tallafawa sakamakon wannan binciken ne daga wakilin da ya dace akan bukatar mai mahimmanci.
Hukumar Lafiya Ta Duniya. Shawarwarin don dabarun gwaji na LaFID-19: Shiryarwar tauji, 21 ga Maris 21, 2020 A'a
Mouuliou, DS, Pantazopoulos, I. & gourgoulianis, ki a cikin 19 wayo mai wayo a cikin sashen gaggawa: duka-ciki a aikace. Mouuliou, DS, Pantazopoulos, I. & gourgoulianis, ki a cikin 19 wayo mai wayo a cikin sashen gaggawa: duka-ciki a aikace.Muliuu, DS, Pantazopoulos, I. da Gurgulian, Ki na gano fahimini game da COVID-19 a cikin Ma'aikatar Gaggawa: Duk abin cikin aiki.Muriuu DS, Pantazopoulos I. Kuma Pantazopoanis KI masu hikimar ganowa game da COVID-19 a cikin sashen gaggawa: haɗin gaggawa a aikace. Masanin hana zunubin. magani. 3, 263-272 (2022).
Mitchell, Sl & St George, K. K. Georte na Coviid19 ID yanzu EUA Assay. Mitchell, Sl & St George, K. K. Georte na Coviid19 ID yanzu EUA Assay.Mitchell, Sl da St. George, K. K. Sihiri da Coviid19 ID yanzu EUA Assay.Mitchell sl da St. George K. Kabarwa na COVID19 ID yanzu EUA Assay. J. Clinical. Ƙwayar cuta. 128, 104429. HTTPS://dii.org/10.1016/j.jcv.2020.104429 (2020) (2020).
HUKUMAR LAFIYA TA DUNIYA. Ginin dakin gwaje-gwaje na cutar Coronavirus cuta 2019 (COVID-19) A cikin zargin cutar ɗan adam. HTTPS://www.who.int/paperōss/i/item/106655-331501 (wanda ya isa) (Waye 2020).
UDugama, B. et al. Cutar da COVID-19 ganewar asali: cututtuka da kayan aikin gwaji. ACS Nano 14 (4), 3822-3835 (2020).
Syed S. et al. Kamfanin Kwalejin Kwalejin Equologist na Gabas, Tsakiya da Kudancin Afirka - Makarantar Yanki na Gabas ta Tsakiya da Afirka ta Kudu. Afirka. J. Lab. magani. 9 (1), 1-8 (2020).
Cibiyar Lafiya ta Habasha ta Lafiyar Jama'a, Ma'aikatar Lafiya ta Tarayya. Interim na kasa dabarun da shiriya don ingantaccen ganewar dakin gwaje-gwaje na CoVID-19. https://ephi.gov.et/Images/Novel_coronavirusus/epho_Kavirususus/PhaboCoC_eng.pdforS_eng
Woloshin, S., Patel, N. & Kanseshheim, kamar yadda gwajin karya na karya don ƙalubale na SARS-2 da abubuwan kamuwa da cuta. Woloshin, S., Patel, N. & Kanseshheim, kamar yadda gwajin karya na karya don ƙalubale na SARS-2 da abubuwan kamuwa da cuta.Voloshin S., Patel N. da Kanselheim a matsayin mummunan gwaje-gwaje don cututtukan SARS-2 da sakamakonsu.Voloshin S., Patel N. da Kanselheim kamar yadda Bala'i-mummunan gwaji don tsokana da tasirin kamuwa da SARS-2. N. Eng. J. magani. 383 (6), E38 (2020).
Mouuliou, DS & Gourgoulianis, ki karya-tabbatacce kuma ƙarya-19 coves: rigakafi na rigakafi da dabarun gudanarwa, alurar riga kafi, da ƙarin ra'ayoyi. Mouuliou, DS & Gourgoulianis, ki karya-tabbatacce kuma ƙarya-19 coves: rigakafi na rigakafi da dabarun gudanarwa, alurar riga kafi, da ƙarin ra'ayoyi. Mouliou, ds & gourgoulianis, ki лоооооооте икая Профияктиа Профилатиа и стратегини лечения, Ваклиницицияя и дерспетиы. Mouuliou, DS & Gourgoulianis, Ki arya tabbatacce kuma karya ne mara kyau na COVID-19: Yin rigakafi da dabarun magani, alurar riga kafi da hanya gaba.Muliu, DS da Gurgulian, Ki arya-tabbatacce kuma karya ne na covid-19: dabarun rigakafi da magani, alurar riga kafi, alurar riga kafi da hanya gaba. Masanin hana zunubin. magani. 15 (8), 993-1002 (2021).
Mouliou, DS, Ioannis, P. & Konstantinos, G. & Konstantinos, G. & Konstantinos, G. & Konstantinos, G. Mouliou, DS, Ioannis, P. & Konstantinos, G. & Konstantinos, G. & Konstantinos, G. & Konstantinos, G.Mouliou, DS, Ioannis, P. da Konstantinos, G. Coviid-19 ganewardan ciki a cikin gaggawa Sashin gaggawa: duba itaciyar, rasa gandun daji.Muriuu DS, Ioannis P., da kuma Konstantinos G. COVID-19 ganewar asali a cikin dakunan gaggawa: ba isasshen gandun daji ga bishiyoyi ba. Bayyana. magani. J. https://dii.org/10.1136/Eeremed-021-2122219 (2022).
Degli-elti, e. et al. Ingantaccen inganci da Ingantaccen nazarin nazarin da asibitin na aikin asibiti na Abbott Realtime SSS-Cov-2 Assayi. J. Clinical. Ƙwayar cuta. 129, 104474. Https://dii.org/10.1016/j.jcv.2020.1044744 (2020).
Mollaei, HR, Afshar, AA, Kalantar-Neyestaniour, D. & Aflatoonan, M. & Aflatoonan, Ch. Mollaei, HR, Afshar, AA, Kalantar-Neyestaniour, D. & Aflatoonan, M. & Aflatoonian, B. Kwatanta kamuwa da cuta na kwayar cutar ta al'ada.Mollaei, HR, Afshar, Afshantar-Neyestaniour, D. da kuma Aflatyan-Neyestaniour, M. da Aflatyan-Neyestani, M. Kuma Aflatyan-Neyestan, M. Kuma Aflatyan-Neyestan, M. Kuma Aflatyan-Neyesan, M. Kuma Aflatyan-Neyesan, da Aflatunyan, da na COMPIDS na covid-19 na gano hoto guda biyar ta hanyar al'ada. Mollaei, HR, Afshar, Aa, Kalantar-Neyestaniour, D. & Aflatoonan, M. & Aflatoonan, M. & Aflatoonan, M. & Aflatoonan, M. Mollaei, HR, Afshar, Afshar-Neyestaniour, D. & Aflatoonan, da Aflatoonan, daban-daban na covid-19 daban-daban yankuna ko bidiyo da na al'ada.Mollaei Hr, Afshar AA, Afshantar-Neyestanaki D, Fazlalipour M. Kuma Afratunan B. Kwanciyar da ke tattare da haɓakar ƙwayoyin cuta guda biyar daga cikin yankuna na al'ada.Iran. J. Microbiology. 12 (3), 185 (2020).
Goertzer, I. et al. Sakamakon farko na tsarin kimantawa na kimantawa na ƙasa don gano jerin hanyoyin SARS-2-2. J. Clinical. Ƙwayar cuta. 129, 104537. Https://dii.org/10.1016/j.jcv.2020.104537 (2020104537 (2020104537 (2020).
Wang, M. et al. Kimarin tantancewa na rinjaye na biyar na PCR don masarautar cututtukan cututtukan jini na gari Coronavirus 2. J. Clinical. dakin gwaje-gwaje. anus. 35 (1), E23643 (2021).
Wang B. et al. Kimiyya da ketare ta bakwai na kasuwanci guda biyu da aka samo yankin SSS-2 a kasar Sin dangane da satar sarkar na gaske (PCR). asibiti. Sunadarai. dakin gwaje-gwaje. magani. 58 (9), E149-E153 (2020).
van Castren, PB et al. Kwatanta da bakwai kasuwanci na kasuwanci na Rtan ciniki bakwai. J. Clinical. Ƙwayar cuta. 128, 104412 (20201).
Lu, yu, et al. Kwatanta rashin bincike game da ayyukan cututtukan cututtukan cututtukan cututtukan biyu guda biyu don ganowar kayan aikin SARS-2. J. Clinical. dakin gwaje-gwaje. anus. 34 (10), E23554 (2020).
LeFART, PR, da sauransu nazarin kwatankwacinsu na gwaji hudu-2-2 nunin kayan gwaji (naat) ya nuna cewa ba a lalata ID ɗin da ke cikin haƙuri ba. ganewar asali. microbiology. Cutar. Nasara. 99 (1), 115200 (2021).
Abbott Molecule. ABDUMT Real-Lokaci-2 Bincike kunshin kunshin kaya. https://www.molecular.Abot/us/usus/ususs/inurous-Disease-sars-caurt-sary-pca-saray-pcov-asse-caury-pcov. 1-12. Kamar 10 ga Agusta, 2020) (2020).
Klein, S. et al. SARS-COV-2 RNA ILOLILACH 2 ta amfani da beads na magnetic don samun saurin sikelin ta hanyar Rtan-qpcr da Rt-QPCR. Virus 12 (8), 863 (2020).